Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/33169
Title: Localization of vascular endothelial growth factor-D in malignant melanoma suggests a role in tumour angiogenesis.
Authors: Stacker S.A.;Minekus M.P.;Thornton G.E.;Stenvers K.;Rogers P.A.W.;Lederman F.;Roufail S.;Achen M.G.;Williams R.A.
Institution: (Achen, Minekus, Stenvers, Rogers, Lederman, Roufail, Stacker) Ludwig Institute for Cancer Research, Royal Melbourne Hospital, Post Office Box 2008, Vic. 3050, Australia (Williams) Department of Pathology, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Parkville, Vic., Australia (Thornton) Monash University, Department of Obstetrics and Gynaecology, Monash Medical Centre, 246 Clayton Road, Clayton, Vic., Australia (Achen) Angiogenesis Laboratory, Ludwig Institute for Cancer Research, Royal Melbourne Hospital, PO Box 2008, Vic. 3050, Australia
Issue Date: 22-Oct-2012
Copyright year: 2001
Publisher: John Wiley and Sons Ltd (Southern Gate, Chichester, West Sussex PO19 8SQ, United Kingdom)
Place of publication: United Kingdom
Publication information: Journal of Pathology. 193 (2) (pp 147-154), 2001. Date of Publication: 2001.
Abstract: Expression of angiogenic and lymphangiogenic factors by tumours may influence the route of metastatic spread. Vascular endothelial growth factor (VEGF) is a regulator of tumour angiogenesis, but studies of the inhibition of solid tumour growth by neutralizing anti-VEGF antibodies indicated that other angiogenic factors may be involved. VEGF-D may be an alternative regulator because like VEGF it is angiogenic and it activates VEGF receptor-2 (VEGFR-2), an endothelial cell receptor which is a key signalling molecule in tumour angiogenesis. This study reports the generation of monoclonal antibodies to the receptor-binding domain of VEGF-D and the use of these antibodies to localize VEGF-D in malignant melanoma. VEGF-D was detected in tumour cells and in vessels adjacent to immunopositive tumour cells, but not in vessels distant from the tumours. These findings are consistent with a model in which VEGF-D, secreted by tumour cells, activates endothelial cell receptors and thereby contributes to the regulation of tumour angiogenesis and possibly lymphangiogenesis. In addition, VEGF-D was detected in the vascular smooth muscle, but not the endothelium, of vessels in adult colon. The endothelium of these vessels was negative for VEGFR-2 and VEGFR-3. As VEGF receptors can be up-regulated on endothelium in response to vessel damage and ischaemia, these findings of a specific localization of VEGF-D in smooth muscle of the blood vessels suggest that VEGF-D produced by vascular smooth muscle could play a role in vascular repair by stimulating the proliferation of endothelial cells. Copyright © 2000 John Wiley & Sons, Ltd.
DOI: http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1002/1096-9896%282000%299999:9999%3C
PubMed URL: 11180159 [http://www.ncbi.nlm.nih.gov/pubmed/?term=11180159]
ISSN: 0022-3417
URI: https://repository.monashhealth.org/monashhealthjspui/handle/1/33169
Type: Article
Appears in Collections:Articles

Show full item record

Page view(s)

12
checked on Feb 7, 2025

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.